RADER, Circuit Judge.
Par Pharmaceutical, Inc. (Par) filed Abbreviated New Drug Application (ANDA) No. 76-218, seeking approval to market and sell a generic version of a glaucoma medication called Xalatan. Because the United States District Court for the District of New Jersey did not abuse its discretion in finding only U.S. Patent No. 5,422,368 (the '368 patent) unenforceable due to inequitable conduct, this court affirms.
I.
Glaucoma is a chronic...
Let's get started
Welcome to the leading source of independent legal reporting
Sign on now to see your case.
Or view more than 10 million decisions and orders.
- Updated daily.
- Uncompromising quality.
- Complete, Accurate, Current.